{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"16"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"11"}]}],"title":"Progression of Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"30"},{"groupId":"OG003","value":"27"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions","groups":[{"description":"RO4929097: 10mg PO QD, GDC-0449: 150 mg PO QD","id":"OG000","title":"RO4929097 10mg"},{"description":"RO4929097: 15 mg PO QD, GDC-0449: 150 mg PO QD","id":"OG001","title":"RO4929097 15 mg"},{"description":"ARM 1 - RO4929097: 15 mg PO QD","id":"OG002","title":"ARM 1 - RO4929097: 15 mg PO QD"},{"description":"ARM 2: GDC-0449 150 mg PO QD and RO4929097 15 mg PO QD","id":"OG003","title":"ARM 2: GDC-0449 150 mg PO QD and RO4929097 15 mg PO QD"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 4 months","title":"Response Rate (CR + PR) as Assessed by RECIST 1.1 (Phase Ib and II)","type":"SECONDARY","unitOfMeasure":"participants"}